This is educational content about an experimental drug
Oral semaglutide, on the other hand, must survive the harsh environment of the stomach to be absorbed
Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
Emerging therapies, including dual and triple agonists and small-molecule oral formulations, demonstrate how targeting multiple pathways and improving delivery can enhance efficacy and patient convenience
GLP-1 drugs (officially known as glucagon-like peptide-1 receptor agonists), may seem like the hottest new thing in the pharmacy world
What were trying to go after is the idea that a physician visit is one visit and then theres a break, sometimes three months, sometimes six months